Assembly Biosciences (ASMB) Total Current Liabilities (2010 - 2026)

Assembly Biosciences' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $35.0 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 24.95% year-over-year to $35.0 million; the TTM figure through Mar 2026 stood at $35.0 million (down 24.95% YoY), while the FY2025 annual figure was $48.8 million, up 2.04% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $35.0 million, down from $48.8 million in the prior quarter.
• The five-year high for Total Current Liabilities was $53.4 million in Q3 2025, with the low at $7.1 million in Q3 2023.
• The 5-year median for Total Current Liabilities is $38.8 million (2024), against an average of $30.8 million.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities plunged 53.87% in 2023, then jumped 483.78% in 2024.
• Assembly Biosciences' Total Current Liabilities stood at $16.3 million in 2022, then soared by 140.7% to $39.2 million in 2023, then climbed by 21.87% to $47.8 million in 2024, then rose by 2.04% to $48.8 million in 2025, then fell by 28.26% to $35.0 million in 2026.
• Business Quant data shows ASMB's Total Current Liabilities at $35.0 million in Q1 2026, $48.8 million in Q4 2025, and $53.4 million in Q3 2025.